Cancer Trials Ireland CLG
This organization has already been registered
Someone in your organization has already registered and setup an account. would you like to join their team?Profile owner : F*************r@c**********s.ie
Mission Statement
Cancer Trials Ireland’s mission is to provide access for cancer patients in Ireland to potentially life altering clinical trials and to make Ireland an attractive and effective location to conduct cancer research. The landscape of clinical trials is changing as we move away from treatments based on tumour site of origin and more towards targeted studies in small numbers of patients spanning disease types but sharing common mutations. In this context, the overall objective is to ensure that Cancer Trials Ireland is fit for purpose to take on the challenge of a two-fold increase in the incidence of cancer on the island of Ireland over the next twenty years.
About This Cause
History We were established in 1996 by a group of cancer consultants. Up to May 2016 we were known as ICORG, the All-Ireland Cooperative Oncology Research Group. We were set up to find answers to cancer and create more opportunities for patients to access cutting edge treatments by putting a formal structure in place to make Ireland more attractive as a location for international cancer research groups. Since 1996 more than 15,000 patients have taken part in more than 350 cancer trials. Over the years we have developed strong links with many leading international cancer research groups, such as ECOG-ACRIN, ANZUP, NRG, TRIO, UNC Cancer Network and CRUK and global pharmaceutical companies. As a result of these positive relationships, Irish patients can access cutting edge research options that previously would only have been available in the United States and some larger European countries. Website and Patient Engagement We changed our name and developed a public-facing website in 2016 in order to present our work to the public. In particular, we want patients and their families to be able to find out more about cancer trials running in Irish hospitals. We provide lay summaries of all of our trials and other organisation's cancer trials on our website. Governance The governance structures at Cancer Trials Ireland have been developed to meet best practice standards, facilitate the growth of the organisation, and ensure that all of its various strands are strategically aligned. The organisation’s Articles of Association were adopted at an Extraordinary General Meeting on the 28th November 2014 and a Board was elected at a subsequent Annual General Meeting in November 2014 under said Articles. About Us We are the leading not for profit cancer research trial organisations in Ireland. We work with the foremost Medical, Surgical and Radiation Oncologists, as well as Haematologists and Research Specialists (Oncology Research Nurses, Translational Scientists, Data Managers, Pharmacists and staff) in Ireland. 98% of all cancer treating specialists in Ireland are members of Cancer Trials Ireland. Last year we enabled, supported and oversaw the running of over 150 trials involving thousands of patients. In addition, our members had 13 articles published in peer reviewed journals, 28 abstracts published and addressed some of the most highly regarded international cancer conferences. Since we were established in 1996, more than 15,000 patients have participated in over 350 cancer trials. We are a not-for-profit registered charity. We are partly funded by the Irish Cancer Society and the Health Research Board (HRB). We also receive greatly appreciated donations from members of the public. Our everyday functions include planning, opening, co-coordinating, supporting, monitoring and auditing cancer trials in Ireland. We provide training, facilitate co-operation between all professionals working in the area and support the development of cancer trials research units around the country. We set policy and champion the opening of more cancer trials in Ireland through engagements with key stakeholders both in Ireland and internationally.